Ascentage Pharma (ADR)
Develops and commercializes hematology therapies in China and global clinical trials.
$17.98
After-hours close−0.02 (−0.08%)
At close$18.00(−3.92%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | $0.02 | −$1.28 | −7,840.4% |
| Aug 2026 | −$0.22 | −$0.32 | −45.5% |
| Aug 2026 | −$0.22 | −$1.30 | −491.0% |
| Mar 2026 | −$0.83 | −$0.65 | +21.7% |
The latest year is open to everyone — the 24 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| Mar 2025 | |||
| Aug 2024 | |||
| Jun 2024 | |||
| Dec 2023 | |||
| Aug 2023 | |||
| Jun 2023 | |||
| Dec 2022 | |||
| Aug 2022 | |||
| Jun 2022 | |||
| Dec 2021 | |||
| Aug 2021 | |||
| Jun 2021 | |||
| Dec 2020 | |||
| Aug 2020 | |||
| Jun 2020 | |||
| Dec 2019 | |||
| Jun 2019 | |||
| Dec 2018 | |||
| Jun 2018 | |||
| Dec 2017 | |||
| Jun 2017 | |||
| Dec 2016 | |||
| Jun 2016 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | $0.02 | −$1.28 | −7,840.4% | $24.1M | $44.0M | +83.1% |
| Aug 19, 2026 | −$0.22 | −$0.32 | −45.5% | $53.6M | $44.5M | −16.9% |
| Aug 18, 2026 | −$0.22 | −$1.30 | −491.0% | $53.6M | $44.9M | −16.4% |
| Mar 24, 2026 | −$0.83 | −$0.65 | +21.7% | $44.4M | $49.5M | +11.5% |
The latest year is open to everyone — the 24 quarters behind it read with an account. Sign in | ||||||
| Aug 20, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Aug 22, 2024 | ||||||
| Jun 30, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Aug 21, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Dec 31, 2022 | ||||||
| Aug 26, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Dec 31, 2021 | ||||||
| Aug 24, 2021 | ||||||
| Jun 30, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Aug 18, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Dec 31, 2019 | ||||||
| Jun 30, 2019 | ||||||
| Dec 31, 2018 | ||||||
| Jun 30, 2018 | ||||||
| Dec 31, 2017 | ||||||
| Jun 30, 2017 | ||||||
| Dec 31, 2016 | ||||||
| Jun 30, 2016 | ||||||